Similarly, early Phase III trial data for CimaVax-EGF, a therapeutic vaccine for stage IIIB/IV NSCLC, suggest reduced efficacy in the context of T cell senescence (192). This evidence concerns the gene EGF and non-small cell lung carcinoma.